Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
Status:
Completed
Trial end date:
2020-11-27
Target enrollment:
Participant gender:
Summary
This feasibility study aims to determine if intermittent dosing is deliverable, based on
patient and professional willingness to take part in a randomised trial evaluating less
rather than the standard durations of treatment. The trial will evaluate treatment
compliance, Progression Free Survival and Quality of Life, to inform whether a subsequent
definitive trial is justified and how it should be designed.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborators:
National Institute for Health Research, United Kingdom Oxford University Hospitals NHS Trust University of Oxford